Consortium will also look for lead drug candidates.
Beactica, GE Healthcare, and Uppsala University are collaborating to develop fragment-based drug discovery technology. The agreement also covers the identification of high-quality leads against an undisclosed protein target from Beactica’s pipeline.
The partnership combines GE Healthcare’s Biacore™ technology with Uppsala University’s enzymology technique using Beactica’s approach to fragment-based drug discovery. The parties will develop the next generation of Biacore surface plasmon resonance instruments and applications.
Beactica was spun out of Uppsala University in August 2006.